ProMIS Neurosciences (PMN) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Key milestones and financial position

• Completed enrollment of 144 patients in a robust, oversubscribed phase 1b Alzheimer's study in December, with full financing secured through upcoming data readouts.

• Raised up to $175 million in an oversubscribed financing round led by top-tier investors, ensuring funding through key clinical milestones.

• Interim analysis of trial data is expected mid-year, with final top-line results anticipated by year-end.

• The study design features monthly dosing over 12 months, dose escalation, and placebo control for early Alzheimer's patients.

• High patient retention and investigator enthusiasm have resulted in over-enrollment and strong trial execution.

Scientific platform and differentiation

• Proprietary EpiSelect platform enables design of highly selective antibodies targeting toxic oligomers, believed to drive neurodegeneration.

• PMN310 is the only antibody in development shown not to bind plaque or monomers, focusing exclusively on toxic oligomers.

• Preclinical studies demonstrate strong efficacy and safety, with no plaque binding and reduced risk of ARIA compared to other therapies.

• The platform supports a pipeline targeting ALS, Parkinson's, and Lewy body dementia, with proof of concept in Alzheimer's expected to validate broader applications.

• The approach is now gaining industry acceptance, with other companies shifting focus to oligomers, but PMN310 remains uniquely selective.

Clinical trial design and endpoints

• The Precise AD trial is a 12-month, placebo-controlled, double-blind, randomized phase 1b study with three ascending doses (5, 10, 20mg/kg).

• Enrolled patients have early Alzheimer's (MCI due to AD), with a homogeneous population screened for disease presence.

• Endpoints include a comprehensive biomarker panel, safety (especially ARIA), and clinical outcomes using FDA-approved measures (CDR sum of boxes, ADAS-Cog).

• The study is powered to detect ARIA, with front-loaded MRIs to capture early events; over 90% of ARIA cases in similar studies occur within six months.

• No treatment-related serious adverse events or ARIA have been observed to date, and dropout rates are significantly lower than industry norms.